Inactive Instrument

Press Releases Paratek Pharmaceuticals, Inc.

Equities

PRTK

US6993743029

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Healthcare & Life Sciences Private Equity Deal Tracker: Gurnet Point And Novo Holdings Acquire Paratek Pharmaceuticals	23-10-05	AQ
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023	23-10-05	AQ
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.	23-09-21	AQ
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S	23-09-18	AQ
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S	23-09-12	AQ
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings	23-09-07	GL
Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital	23-08-22	PR
Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal Rights	23-08-09	BU
Paratek: Q2 Earnings Snapshot	23-08-03	AQ
Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million	23-08-03	AQ
Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings	23-08-02	AQ
Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital	23-07-12	PR
NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital	23-07-11	PR
Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax	23-07-10	AQ
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter	23-06-27	AQ
European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease	23-06-27	AQ
PRTK Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Paratek Pharmaceuticals to Gurnet Point Capital and Novo Holdings	23-06-20	AQ
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023	23-06-12	AQ
PRTK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Paratek Pharmaceuticals, Inc. Is Fair to Shareholders	23-06-11	BU
Shareholder Alert: Ademi LLP investigates whether Paratek Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Gurnet Point Capital and Novo Holdings	23-06-08	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Paratek Pharmaceuticals, Inc.

Equities

PRTK

US6993743029

Press Releases

Filters